MYC and hepatocellular carcinoma: Indeed, as the c-MYC pathway is often activated along with other oncogenic pathways in clinical HCC, recent studies have identified various pathways, such as AKT, YAP/TAZ, β-catenin, and RAS pathways, which could collaborate with the c-MYC pathway and exacerbate the c-MYC-mediated oncogenic processes [3, 12–14].